Literature DB >> 26458486

Atypical optic neuritis due to tuberculosis.

Nataraja Pillai Venugopal1.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26458486      PMCID: PMC4652258          DOI: 10.4103/0301-4738.167110

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Sir, We read with interest the article titled “A case of subretinal tubercular abscess presenting as disc edema” by Shetty et al.[1] Authors have mentioned about the difficulty to decide whether the first episode of defective vision is due to demyelinating optic neuritis (DON) or atypical optic neuritis (AON). Asian race, pain persistent for >2 weeks from the onset of defective vision and worsening of vision for >2 weeks are a feature of AON.[2] In Shetty et al.[1] case report, an Asian patient, had pain persisting for 25 days and gradually progressive loss of vision in left eye since 20 days. The disc swelling of DON is diffuse and the presence of segmental changes, altitudinal swelling, pallor, arterial attenuation, and splinter hemorrhages should bring its diagnosis into question. In Shetty et al. case report the disc edema is pronounced and elevated in the upper temporal quadrant. In DON, the disc is normal in 65% of patients (retrobulbar neuritis).[3] If disc edema is present in DON, it is mild and diffuse. To conclude, from above-mentioned features the first episode of defective vision may be due to tuberculous AON.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  3 in total

1.  Clinical approach to optic neuropathies.

Authors:  Raed Behbehani
Journal:  Clin Ophthalmol       Date:  2007-09

Review 2.  Optic neuritis: a review.

Authors:  P N Shams; G T Plant
Journal:  Int MS J       Date:  2009-09

3.  A case of subretinal tubercular abscess presenting as disc edema.

Authors:  Sachin Bermu Shetty; Mohammad Abdullah Bawtag; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.